Rosiglitazone response in diabetics
Rosiglitazone is an oral drug that reduces the amount of sugar (glucose) in the blood, diminishing insulin resistance in the adipose tissue, the skeletal muscle and the liver.
Rosiglitazone is used along with a diet and exercise program and sometimes with one or more other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood).
Rosiglitazone is indicated as an oral stand-alone drug for patients with diabetes mellitus type 2, especially for overweight patients, inadequately controlled by diet and exercise, for whom metformin is not appropriate due to contraindications or intolerance.
Rosiglitazone is also prescribed in combination for the oral treatment of type 2 diabetes mellitus in patients with insufficient glucose control despite receiving the maximum tolerated dose in metformin or sulfonylurea monotherapy:
- Combined with metformin only for obese patients
- Combined with sulfonylurea only for patients with intolerance to metformin or those patients for whom metformin is contraindicated
Rosiglitazone is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated).
Rosiglitazone may cause side effects, some of which may be serious:
- runny nose and other cold symptoms
- sore throat
- back pain
- pain in the jaw, arm, back, neck, or stomach
- chest pain
- breaking out in a cold sweat
- loss of appetite
- stomach pain
- dark urine
- yellowing of the skin or eyes
- changes in vision
- vision loss
- pale skin
- swelling of the eyes, face, lips, tongue, or throat
- difficulty swallowing or breathing
Gene or region studied